The biopharma Atai Life Sciences (Nasdaq:ATAI) subsidiary GABA Therapeutics is sharing positive results from a Phase 1 study of GRX-917, a deuterated form of etifoxine, which the German firm Hoechst developed in the 1960s. Sanofi-Aventis eventually subsumed Hoechst in 2004. Atai investigated the safety, tolerability and pharmacokinetic profile of orally administered GRX-917 in a Phase…
Atai subsidiary wraps up enrollment for clinical study of r-ketamine
Mental health–focused biopharma Atai Life Sciences (Nasdaq:ATAI) recently completed enrollment in a Phase 2a study of PCN-101 (r-ketamine) for treatment-resistant depression. The company’s Perception Neuroscience division expects top-line results from the trial before the end of 2022. R-ketamine is an enantiomer of ketamine. Conversely, racemic ketamine is composed of equal amounts of s-ketamine and r-ketamine.…
Atai Life Sciences shares positive results from Phase 1 study of opioid use disorder
Berlin-headquartered Atai Life Sciences (Nasdaq:ATAI) is sharing positive initial results from a Phase 1 clinical study of KUR-101, an oral formulation of deuterated mitragynine, in patients with opioid use disorder. Mitragynine is a primary active alkaloid of the kratom plant (Mitragyna speciosa). Atai’s KUR-101 is an oral formulation of deuterated mitragynine. Atai subsidiary Kures is leading the…
Atai Life Sciences launches Phase 1 study of buccal and IV synthetic DMT
Atai Life Sciences (Nasdaq:ATAI) has dosed the first patient in a Phase 1 single-ascending-dose study focused on VLS-01, a synthetic form of N,N-dimethyltryptamine (DMT) for treatment-resistant depression (TRD). While many companies in the psychedelic industry first focused on psilocybin, a growing number of players are beginning to explore the therapeutic potential of DMT, a short-acting naturally-occurring…